Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Public ClinicalTrials.gov record NCT02605915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without docetaxel) or atezolizumab and trastuzumab emtansine in participants with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) and locally advanced early breast cancer (EBC), and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer.
Study identification
- NCT ID
- NCT02605915
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 98 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Carboplatin Drug
- Docetaxel Drug
- Pertuzumab Drug
- Trastuzumab Drug
- Trastuzumab emtansine Drug
- Doxorubicin Drug
- Cyclophosphamide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2015 (Actual)
- Primary completion
- Nov 13, 2019 (Actual)
- Completion
- Nov 13, 2019 (Actual)
- Last update posted
- Feb 5, 2020
2015 – 2019
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3300 | — |
| University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute | Little Rock | Arkansas | 72205 | — |
| Joliet oncology hematology associates | Joliet | Illinois | 60435 | — |
| Horizon Oncology Research, Inc. | Lafayette | Indiana | 47905 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21287 | — |
| Karmanos Cancer Center; Department of Oncology | Detroit | Michigan | 48201 | — |
| HCA Midwest Division | Kansas City | Missouri | 64132 | — |
| Montefiore Medical Center, Advanced Women's Health Center, Clinical Trials and Research Unit; Depart | The Bronx | New York | 10461 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Kimmel Cancer Center Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Magee Womens Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street | Chattanooga | Tennessee | 37404 | — |
| West Clinic | Germantown | Tennessee | 38138 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Cancer Therapy and Research Center CTRC at UTHSCSA | San Antonio | Texas | 78229 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02605915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2020 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02605915 live on ClinicalTrials.gov.